Tesamorelin is a synthetic peptide designed to stimulate the body's natural production of growth hormone, a hormone involved in metabolism, tissue maintenance, and the way the body processes fat. Rather than acting as growth hormone itself, tesamorelin works by activating the signals that tell the pituitary gland to release it. This has made tesamorelin an important subject of research into abdominal fat, body composition, and metabolic health.

Research has examined how tesamorelin influences growth hormone release, fat distribution, and the body's ability to regulate stored fat. One area of particular interest is visceral fat, the fat stored deep inside the abdomen around internal organs. Unlike fat directly beneath the skin, excess visceral fat is associated with several metabolic health concerns, making it an important measurement in clinical research.

Tesamorelin has been studied in human clinical trials, particularly among adults living with HIV who experience abnormal abdominal fat accumulation. These studies demonstrated reductions in visceral abdominal fat and led to regulatory approval of specific tesamorelin medicines for this condition in the United States. Additional research has explored its relationship to liver fat, metabolic markers, and body composition.

Although tesamorelin has an established clinical research history, its approved medical use is specific and does not extend to general weight loss or anti-aging treatment. Researchers continue to investigate its effects in different populations, including questions surrounding long-term metabolic outcomes, safety, and the broader significance of changes in abdominal fat.